|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2011-8-8
|
|
pubmed:abstractText |
Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or alone in patients previously treated with a fluoropyrimidine. We compared toxicity (particularly diarrhoea), quality of life, and efficacy of combination chemotherapy and irinotecan in these patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
pubmed-author:Australasian Gastro-Intestinal Trials Group,
pubmed-author:BolandAmyA,
pubmed-author:BrownChrisC,
pubmed-author:BuckMartinM,
pubmed-author:ClarkeStephen JSJ,
pubmed-author:GebskiValV,
pubmed-author:GoldsteinDavidD,
pubmed-author:JeffreyG MarkGM,
pubmed-author:LowenthalRaymond MRM,
pubmed-author:RansomDavid TDT,
pubmed-author:SimesR JohnRJ,
pubmed-author:TebbuttNiall CNC,
pubmed-author:YipSoniaS,
pubmed-author:ZalcbergJohnJ,
pubmed-author:van HazelGuy AGA
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1826-36
|
|
pubmed:meshHeading |
pubmed-meshheading:21665462-Adult,
pubmed-meshheading:21665462-Aged,
pubmed-meshheading:21665462-Aged, 80 and over,
pubmed-meshheading:21665462-Alopecia,
pubmed-meshheading:21665462-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:21665462-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21665462-Camptothecin,
pubmed-meshheading:21665462-Chemotherapy, Adjuvant,
pubmed-meshheading:21665462-Colorectal Neoplasms,
pubmed-meshheading:21665462-Diarrhea,
pubmed-meshheading:21665462-Drug Administration Schedule,
pubmed-meshheading:21665462-Female,
pubmed-meshheading:21665462-Fluorouracil,
pubmed-meshheading:21665462-Humans,
pubmed-meshheading:21665462-Infusions, Intravenous,
pubmed-meshheading:21665462-Injections, Intravenous,
pubmed-meshheading:21665462-Leucovorin,
pubmed-meshheading:21665462-Male,
pubmed-meshheading:21665462-Middle Aged,
pubmed-meshheading:21665462-Neoplasm Staging,
pubmed-meshheading:21665462-Research Design,
pubmed-meshheading:21665462-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis.
|
|
pubmed:affiliation |
Department of Medicine, Concord Hospital, Concord, Sydney, Australia. stephen.clarke@sydney.edu.au
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Meta-Analysis
|
